Growth hormone releasing peptides
Your pituitary gland releases growth hormone in pulses, mostly at night, and that output declines with age. Growth hormone releasing peptides — sermorelin, ipamorelin, CJC-1295, tesamorelin — are studied for nudging the body's own pulses rather than replacing the hormone outright.
The articles below cover how each one works, how they differ from one another and from HGH itself, and what the research does and doesn't show. All of them are prescription-only through Promise: a licensed provider reviews every request.
11 articles on this topic
-
Sermorelin vs CJC-1295: What Actually Differs
Both signal the pituitary through the GHRH pathway. The practical difference is duration: sermorelin is brief, while DAC-bearing CJC-1295 was engineered to remain active far longer.
-
Tesamorelin Dosage: How Prescribers Set It
Tesamorelin is dosed daily in the trials and current brand label, but the milligram amount depends on the formulation. IGF-1, glucose, indication and tolerability matter more than a copied schedule.
-
CJC 1295 Ipamorelin Dosage: What Studies Used
There is no validated combined dose. Human studies used different formulations, routes and objectives, so a prescriber has to identify the exact product, interpret the clinical context and set the schedule.
-
Sermorelin Dosing: How Prescribers Set a Dose
There is no single established adult dose. Nighttime is common because sermorelin works through the body's pulsatile growth-hormone system, while the amount and titration depend on the person, the formulation and the prescriber's clinical judgment.
-
Sermorelin Benefits: What the Trials Found
In the best controlled study of GHRH in older adults, nocturnal growth hormone rose, IGF-1 climbed within two weeks, skin thickened — and lean body mass increased in men only. The specificity is the point.
-
Sermorelin Side Effects, by the Numbers
About one patient in six gets a reaction where the needle went in. Almost everything else on the list occurs in under 1% — but the trial data behind those numbers comes from a population that may not look like you.
-
Ipamorelin Benefits, Side Effects, Legal Status
Developed at Novo Nordisk in the late 1990s, ipamorelin is a five-amino-acid peptide that released growth hormone in animal studies without raising cortisol even at more than 200 times its effective dose.
-
AOD-9604 Peptide: Fat-Loss Hype vs the Record
Six placebo-controlled trials in 893 obese adults — capped by a 536-subject study that missed its endpoints — ended AOD-9604's drug development in 2007.
-
What Does Tesamorelin Do?
In 26-week Phase 3 trials, daily tesamorelin reduced visceral abdominal fat by 10.9–15.4% in adults with HIV-associated lipodystrophy while placebo groups gained fat.
-
CJC-1295 and Ipamorelin: Why They're Paired
One prescription, two receptors: CJC-1295 signals through the GHRH receptor while ipamorelin mimics ghrelin at GHSR-1a — two separate inputs to the same growth-hormone axis.
-
Sermorelin vs HGH: What Is the Difference?
Sermorelin is a synthetic copy of the first 29 amino acids of growth-hormone-releasing hormone — a fragment that keeps the full GH-releasing activity of the 44-amino-acid original — while HGH therapy injects the finished hormone itself.